DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alzheimer's Disease (AD)

Intervention: lorazepam (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Mayo Clinic

Official(s) and/or principal investigator(s):
Cynthia Stonnington, MD, Principal Investigator, Affiliation: Mayo Clinic

Overall contact:
Jan A Light, LPN, Phone: (480) 301-8788, Email: Light.Jan@mayo.edu

Summary

The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.

Clinical Details

Official title: The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

AVLT Long term memory score

Groton Maze Learning Test (GMLT) score

Eligibility

Minimum age: 50 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion criteria:

- MMSE score of 28-30

- Hamilton Depression Rating Scale score of less than 10

- participants in longitudinal study of aging and have a TOMM40 genotype of S/S, VL/VL,

S/VL, L/S or L/VL. Exclusion criteria:

- Alzheimer's Disease or Mild Cognitive Impairment

- any significant medical, psychiatric, and neurological illnesses, e. g., impaired

liver or kidney function, prior stroke, traumatic brain injury, memory impairment, cognitive impairment, parkinsonism, a lifetime history of schizophrenia, bipolar disorder, a psychoactive substance use disorder, or current major depression.

- known allergy to benzodiazepines

- current use (within the previous four weeks) of benzodiazepines or other medications

known to interact with lorazepam, current use of sedating antihistamines, or current use of stimulant medications

Locations and Contacts

Jan A Light, LPN, Phone: (480) 301-8788, Email: Light.Jan@mayo.edu

Mayo Clinic, Scottsdale, Arizona 85259, United States; Recruiting
Additional Information

Starting date: January 2013
Last updated: April 10, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017